Indeed, treatment with CET-CH-6 synergistically enhances the therapeutic effects of TMZ and doxorubicin in P53-mutant glioma cell lines by inhibiting NRF2, both in vitro and in vivo [122]. The gene discussed is NFE2L2; the disease is central nervous system cancer.